Colorectal Cancer Outcomes in a Large Negative Computed Tomography Colonography Screening Cohort

• Published in: Canadian Association of Radiologists Journal
• Main Authors: McComiskey, David A., Barrett, Brendan, Flemming, Jeffrey, McKay, Kathy, Sala, Eric
• Format: Article in Journal/Newspaper
• Language: English
• Published: SAGE Publications 2019
• Subjects: Newfoundland; Canada
• Online Access: http://dx.doi.org/10.1016/j.carj.2018.09.009; https://api.elsevier.com/content/article/PII:S0846537119300488?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:S0846537119300488?httpAccept=text/plain; http://journals.sagepub.com/doi/pdf/10.1016/j.carj.2018.09.009; http://journals.sagepub.com/doi/full-xml/10.1016/j.carj.2018.09.009

Introduction At our institution, the most common cohort of individuals having computed tomography colonography (CTC) are those that require primary screening for colorectal cancer and were unable to tolerate or failed optical colonoscopy (OC). CTC is an efficient method for detecting polyps, masses, flat-lesions, and overt colorectal cancer, serving as a viable alternative to colonoscopy. This study follows patients with negative CTC results to evaluate the number of clinically significant lesions that may have been potentially missed by CTC. We suspect this number will be exceedingly low given the high sensitivity of this technique. Methods All patients with negative CTC screening (n = 509) in the Eastern Health Medical Health Region, located in Newfoundland and Labrador, Canada were included. An electronic medical record review was undertaken, encompassing provider, colonoscopy, imaging, and histopathology reports. Subjects were also checked through the Newfoundland Cancer Clinic Registry Database. All incidents of colorectal cancer were recorded. Results The study cohort comprised 509 subjects. These subjects were followed for an average of 7.88 years. Two colorectal adenocarcinomas in this cohort were identified representing a crude cancer incidence rate of 0.49 cancers per 1000 patient years, and a rate of 0.39% following a normal CTC. Conclusions Colorectal cancer presenting clinically is rare in the 7.88 years following a negative CTC, suggesting CTC is equally effective for colorectal screening compared to OC. Furthermore, current guidelines that recommend interval CTC screening every 5 years is conservative, and interval screening can likely be recommended over a longer time frame.